Immuron CEO Steven Lydeamore to Present at Emerging Growth Conference

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company, announced that its Chief Executive Officer, Steven Lydeamore, will present at the Emerging Growth Conference on August 19, 2026. The virtual presentation is scheduled for 4:25 PM – 4:35 PM U.S. Eastern Time. The filing also provides a comprehensive overview of Immuron’s product portfolio and platform technology, which utilizes polyclonal antibodies derived from hyper-immune bovine colostrum to treat infectious diseases. Key products highlighted include Travelan®, an orally administered immunotherapy for the prevention of travelers’ diarrhea; IMM-529, an investigational therapy for Clostridioides difficile infection (CDI) currently in development with Monash University; and ProIBS®, a certified medical device for irritable bowel syndrome symptoms distributed in Australia and New Zealand. The company emphasized that its technology platform allows for the development of medicines targeting various enteric pathogens by neutralizing viruses and bacteria in the gastrointestinal tract. No new clinical data or financial results were disclosed in this announcement.